3Wood D,De Backer G,Faergeman O,et al.Prevention of coronary heart disease in clinical practice.Recommendations of the second joint tacle force of European and other societies on coronary prevention[J].Eur Heart J,1998,19:1434-1503.
4National cholesterol education program.Cholesterol lowering in the patient with coronary heart disease[S].Washing DC:U.S.department of health and human services,public health service,National institute of health,national heart,lung and blood institute,1997,3794.
5British cardiac society and medical practice committee,and royal college of physicians clinical effectiveness and evaluations unit.Guildline for the management of patients with acute coronary symdromes without persistent ECG ST segment elevation[J].Heart,2001,85:133-142.
6Antiplatelet trialists collaboration.Collaborative overview of antiplatelet therapy-1:prevention of death,myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients[J].BMJ,1994,108:81-106.
7Theroux P,Quimet H,McCans J,et al.Aspirin,heparin,or both to treat acute unstable angina[J].New England J Med,1983,309:1105-1111.
8Kong DF,Califf RM,Miller DP,et al.Clinical outcomes of therapeutic agents that block the platelet glyciprotein Ⅱb/Ⅲa integrin in ischemic heart disease[J].Circulation,1998,98:2828-2835.
9Hamm CW,Heeschen G,Goldmann BU,et al.For the CAPTURE study investigators.troponin T predicts the benefit of abciximab in patients with unstable angina in the CAPTURE study[J].New England J Med,1999,340:1623-1629.
10Boersma E,Akkerhuis KM,Theroux P,et al.Platelet receptor GP Ⅱb/Ⅲa recepter inhibition in non ST-elevation acute coronary syndrom:early benefit during medical treatment only,with additional protection during percutaneous coronary intervention[J].Circulation,1999,100:2045-2048.
